Novacyt

Novacyt Change in Working Capital

The Change in Working Capital of Novacyt (ALNOV.PA) as of Oct 18, 2026 is -650,952.00 GBP. In the previous year, Change in Working Capital was 31.83 M GBP — a change of -102.04% (lower).

Change in Working Capital

-650,952.00GBP

YoY

-102.04%

Last updated:

Change in Working Capital of Novacyt is 2025 -650,952.00 GBP. Change in Working Capital of Novacyt was 2024 31.83 M GBP. It decreases by -102.04% lower compared to the previous year.

The Novacyt Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
986,259.70 GBP
Jan 1, 2019
948,730.30 GBP
Jan 1, 2020
-71.90 M GBP
Jan 1, 2021
37.19 M GBP
Jan 1, 2022
-2.57 M GBP
Jan 1, 2023
-6.36 M GBP
Jan 1, 2024
31.83 M GBP
Jan 1, 2025
-650,952.00 GBP
The Novacyt Change in Working Capital history
YEARChange in Working CapitalYoY
-650,952.00GBP-102.04%
31.83 MGBP-600.77%
-6.36 MGBP+147.84%
-2.57 MGBP-106.90%
37.19 MGBP-151.72%
-71.90 MGBP-7,678.66%
948,730.30GBP-3.81%
986,259.70GBP-166.42%
-1.48 MGBP-249.66%
992,175.60GBP-157.44%
-1.73 MGBP-263.72%
1.06 MGBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Change in Working Capital of Novacyt is -650,952.00 GBP in 2025.

Change in Working Capital of Novacyt changed from 31.83 M GBP to -650,952.00 GBP, representing a -102.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Novacyt since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Novacyt historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Novacyt

All Key Metrics — Novacyt